Raymond James Downgrades Monopar Therapeutics to Outperform, Lowers Price Target to $123
Benzinga Newsdesk 11 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers the price target from $142 to $123.
Raymond James analyst Chris Raymond downgrades Monopar Therapeutics (NASDAQ:MNPR) from Strong Buy to Outperform and lowers the price target from $142 to $123.